MOUNTAIN VIEW, CA — (Marketwired) — 05/11/15 — Hansen Medical®, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced it will exhibit its Sensei® X2 Robotic System at the Heart Rhythm Society–s (HRS) Annual Scientific Sessions, May 13 – 15 at the Boston Convention & Exhibition Center in Boston, Massachusetts. Hansen will highlight the new Sensei X2 Robotic System, which features faster processing, enhanced image integration and a slimmer design. The Company will be conducting product demonstrations and displaying the Sensei X2 Robotic System at Booth 843.
In addition, the Sensei Robotic System will be featured in a poster presentation during the conference. On Saturday, May 16 from 9:30 am to 12:00 pm, Juergen Schreieck, MD, from the Medical University of Tuebingen in Tuebingen, Germany, will present his clinical findings on force sensing with the robotic navigation system in a poster presentation.
“We are pleased to see new data presented on Sensei at HRS, one of the biggest cardiac conferences of the year,” said Cary Vance, President and Chief Executive Officer of Hansen Medical. “This study represents continued momentum behind the unique combination of force sensing technology and the stability and control of the Sensei System.”
About Sensei Robotic System
Sensei Robotic System combines advanced levels of 3D catheter control and 3D visualization. This unique, state of the art technology has been used in over 14,000 patients, and is powered by a robotically controlled arm that allows for catheter navigation, stability and positioning within the patient–s heart atria. The Sensei Robotic System, control catheters and accessories are intended to facilitate manipulation, positioning and control of Hansen Medical–s robotically steerable catheters for collecting electrophysiological data within the heart atria with electro-anatomic mapping and recording systems, using specified percutaneous mapping catheters. The Sensei Robotic System is powered by a robotically controlled arm that allows for catheter navigation and stability. The safety and effectiveness of this device for use with cardiac ablation catheters, in the treatment of cardiac arrhythmias including atrial fibrillation, have not been established.
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is the global leader in Intravascular Robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company–s Magellan Robotic System, 9Fr Magellan Robotic Catheter, Magellan 6Fr Robotic Catheter, and related accessories are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Company–s mission is to enable Cardiac Arrhythmia and Endovascular Procedures and to improve patient outcomes through the use of Intravascular Robotics. Additional information can be found at .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “plan,” “expects,” “potential,” “believes,” “goal,” “estimate,” “anticipates,” and other similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements regarding the potential benefits of our robotic systems for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: factors relating to engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of credit, financial and economic conditions on capital spending by our potential customers; the rate of adoption of our systems and the rate of use of our catheters; our ability to manage expenses and cash flow, and obtain adequate financing; and other risks more fully described in the “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2014, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
“Hansen Medical,” “Hansen Medical (with Heart Design),” “Heart Design (Logo),” and “Sensei” are registered trademarks, and “Magellan” is a trademark, of Hansen Medical, Inc. in the U.S. and other countries.
You must be logged in to post a comment Login